AMNEAL PHARMACEUTICALS INC CLASS A (AMRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for AMRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AMRX | Managing Partner; Director | 52 | ["CEO, General Management, Commercial", "Corporate Development, Business Development, M&A", "Investment, Private Equity", "International"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| LENZ | Chair | 52 | [] | [] | 2026 |
Biography sourced from the proxy statement filing.
Jeff George has over 25 years of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He is currently the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded in 2017. Between 2008 and 2016, he served on the Executive Committee of Novartis Group AG, one of the largest global pharmaceutical companies, first as Division Head and CEO of Sandoz, Novartis' $10 billion generic pharmaceuticals and biosimilars subsidiary, which is now publicly listed, and then as Division Head and CEO of Alcon, Novartis' then $10 billion branded eye care subsidiary, which was spun out of Novartis in 2019 as a publicly listed company. In both roles, he was responsible for leading over 25,000 associates globally across more than 160 countries. Mr. George previously headed Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharmaceuticals and served as Vice President and Head of Western & Eastern Europe for Novartis Vaccines. Prior to this, he held leadership roles at Gap Inc. and McKinsey & Co. Mr. George currently serves as Chairman of the Board of Directors at LENZ Therapeutics, a Nasdaq-listed ophthalmic biotech company. Until 2025, he also served on the Board of Directors of 908 Devices, a Nasdaq-listed pioneer in life science diagnostics (which divested its biopharma business in 2025), and Dorian Therapeutics, a Silicon Valley-based cellular senescence biotech spun out of Stanford University which was sold in 2025. He also served as Chairman of the board of Lykos Therapeutics, a late clinical-stage CNS-focused biopharma company, from 2022 to 2025, as well as numerous non-profit boards. He holds an MBA from Harvard Business School, an M.A. from Johns Hopkins University's School of Advanced International Studies (SAIS), and a B.A. from Carleton College. Skills and Qualifications: CEO, General Management, Commercial Corporate Development, Business Development, M&A Investment, Private Equity International